ANTERIS TECHNOLOGIES GLOBAL SEC Filings

Anteris Technologies Global Corp. announced that its Board appointed Susan Knight and Stephen Denaro as directors effective May 11, 2026 (May 12, 2026 in Australia). Knight becomes a Class I director with a term running to the 2028 annual meeting and will join the Audit and Risk Committee. Denaro becomes a Class II director with a term running to the 2026 annual meeting. As non-employee directors, they will receive cash retainers and equity compensation under the company’s Non-Employee Director Compensation Policy, including an initial restricted stock unit grant to Knight valued at $250,000, subject to stockholder approval, and potential annual RSU awards valued at $125,000. Denaro also receives an annual fee of AUD $57,645 for serving as company secretary to certain Australian subsidiaries. The company entered into indemnification agreements with both directors, providing protection to the fullest extent permitted under Delaware law.

Anteris Technologies Global Corp. furnished its first-quarter 2026 results, highlighting heavy investment in its pivotal DurAVR heart valve trial. For the three months ended 31 March 2026, net operating cash outflows were $28.7 million, mainly tied to clinical, regulatory and manufacturing work on the Trial.

Research and development expenses were $17.5 million, driven by expanded manufacturing, quality processes, added headcount and clinical costs as more patients were enrolled. The company also reported related-party payments of $2.3 million for director fees and executive compensation during the quarter. The Trial is a ~1,000-patient randomized study comparing the DurAVR transcatheter valve to existing TAVR devices, supported in the U.S. by Medicare and Medicaid coverage under National Coverage Determination 20.32.

Anteris Technologies Global Corp. reported a larger quarterly operating loss as it scales development of its DurAVR THV heart valve, but now holds a significantly stronger cash position after major equity financings. For the three months ended March 31, 2026, net sales were $0.5 million, down slightly from $0.6 million a year earlier, reflecting the wind-down of legacy product distribution.

Research and development expense rose to $17.5 million and selling, general and administrative costs to $6.9 million, driving a net loss of $22.9 million compared with $21.9 million in 2025. Other income increased to $1.7 million, mainly from interest on cash.

The company strengthened its balance sheet with a January 2026 underwritten public offering of 40.0 million shares and a 15.7 million-share private placement to Medtronic at $5.75 per share, generating about $320 million in gross proceeds. Cash, cash equivalents and restricted cash rose to $283.2 million from $12.6 million, and stockholders’ equity improved to $278.4 million from a small deficit, despite an accumulated deficit of $393.6 million. Management believes current cash will fund operations for at least 12 months.

Operationally, Anteris advanced its global pivotal Trial for DurAVR THV, supported by FDA IDE approval and, in April 2026, U.S. Medicare reimbursement eligibility under an existing TAVR coverage determination, enabling U.S. site activation and initial patient enrollment in May 2026. The company continues to consolidate a variable interest entity, v2vmedtech, but has elected to terminate its development agreement after quarter-end, incurring a $0.4 million break fee and removing ongoing funding obligations.

Management again disclosed that disclosure controls and procedures were not effective due to previously identified material weaknesses in internal control over financial reporting, although remediation efforts, including enhanced segregation of duties and control documentation, are under way. Anteris remains an emerging growth and smaller reporting company and expects continued losses as it invests heavily in clinical, regulatory, and manufacturing capabilities to pursue FDA Premarket Approval and CE Mark for DurAVR THV.

Anteris Technologies Global Corp. ownership disclosure: Sio Capital Management, LLC amended its Schedule 13G to report beneficial ownership of 5,382,965 shares of Common Stock as of March 31, 2026. The filing states this represents 5.54% of the class based on 97,232,054 shares outstanding as of February 25, 2026.

The statement clarifies voting and dispositive power as shared and explains relationships among Sio, Sio GP, LLC and Michael Castor; the filing includes a disclaimer about formal beneficial‑owner attribution.

Anteris Technologies Global Corp. files a Prospectus Supplement to its Form S-1 registering up to 9,103,796 shares of common stock for resale by selling stockholders. The supplement attaches a Form 8-K disclosing that the company elected to discontinue further development contributions to v2vmedtech, inc., triggering termination of a related Development Agreement upon payment of a $400,000 break fee. The company states it does not expect these actions to have a material adverse effect on consolidated financial position or liquidity.

Anteris Technologies Global Corp., through its subsidiary Anteris Technologies Corporation, has elected to discontinue additional development contributions under its Contribution and Stock Purchase Agreement with v2vmedtech, inc., following completion of Stage 1 and during Stage 2 of the development program.

As a result, the related Development Agreement dated April 18, 2023 will terminate upon payment of a $400,000 break fee. Anteris states it does not expect this discontinuation of contributions and the termination of the Development Agreement to have a material adverse effect on its consolidated financial position or liquidity.

BlackRock, Inc. reports beneficial ownership of 4,879,068 shares of ANTERIS TECHNOLOGIES GLOBAL CORP common stock, representing 5.01% of the class as of 03/31/2026. The filing lists sole voting power for 4,810,606 shares and sole dispositive power for 4,879,068 shares. The Schedule 13G was signed by Spencer Fleming on 04/27/2026 and notes holdings reflect securities held by certain Reporting Business Units of BlackRock.

Anteris Technologies Global Corp. files a prospectus supplement updating its Registration Statement to cover the resale of up to 9,103,796 shares of Common Stock by the selling stockholders named in the Prospectus. The supplement attaches a Form 8-K reporting a new lease.

The Form 8-K discloses a lease through a wholly owned subsidiary for approximately 181,436 square feet in Brooklyn Park, Minnesota, with an initial term from September 1, 2026 to August 31, 2037. The lease specifies an initial monthly minimum rent of $152,708.63, contractual rent abatements (first three months fully abated, succeeding nine months partially abated), annual escalations, and payment of taxes and operating expenses. The lease description is qualified by the full lease to be filed as an exhibit to the Company’s Form 10-Q.

Anteris Technologies Global Corp. has entered into a long-term lease for approximately 181,436 square feet of office and warehouse space in Brooklyn Park, Minnesota, through its wholly owned subsidiary Anteris Technologies Corporation.

The lease starts on September 1, 2026 and runs through August 31, 2037, with options to extend for two additional 84‑month periods at market rent. Initial monthly minimum rent is $152,708.63, subject to contractual abatements, annual escalations and other adjustments, plus real estate taxes, operating expenses and other charges. Rent is fully abated for the first three months and partially abated for the following nine months, which eases cash outlay during the initial occupancy period.